ALLO Hit With Bull Notes After Posting Positive Drug Data

Allogen stock is trading right back near its all-time highs

Deputy Editor
May 14, 2020 at 9:34 AM
facebook twitter linkedin

Allogene Therapeutics Inc (NASDAQ:ALLO) this morning released well-received data from its phase-one study of its non-Hodgkin lymphoma treatment, ALLO-501. The oncology firm expects to initiate the next steps of its phase-one study of the therapy in the second quarter of this year. In response, ALLO is up 16.2% to trade at $36. 

The announcement sparked no less than four price-target hikes from analysts, the highest coming from Oppenheimer, which lifted its price target to $50 from $44. Suntrust Robinson, meanwhile, downgraded ALLO to "hold" from "buy," while lifting its price estimate to $32 from $29.

Coming into today, the 12-month consensus price target of $37.31 sat at a 21.2% premium to last night's close, with 11 covering the stock call it a "buy" or better, while five say "hold." 

Today's pop puts ALLO right in line with its May 12, record high of $35.61, and back north of a long-term ceiling at the $34 level, which has thwarted countless breakout attempts since the stock went public in 2018. For the year, ALLO is up over 20%, with the 20-day moving average swooping in to catch yesterday's pullback.

This positive price action has prompted some short sellers to start hitting the exits, with short interest down 6.7% in the last reporting period. There's still plenty of pessimism to be unwound here, however. The 13.17 million shares sold short make up over a quarter of ALLO's available float. In other words, it would take 17.4 days to cover all these bearish bets, at the security's average pace of trading. 


Special Offers from Schaeffer's Trading Partners